<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916328</url>
  </required_header>
  <id_info>
    <org_study_id>CO-EU-380-5327</org_study_id>
    <nct_id>NCT03916328</nct_id>
  </id_info>
  <brief_title>BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study</brief_title>
  <acronym>BONE:STAR</acronym>
  <official_title>A Phase IV Open-Label Trial to Assess Bone Mineral Density in a Cohort of African Women on Depo-provera and Tenofovir Disoproxil Fumurate Switched to Tenofovir Alafenamide Fumarate Based Anti-Retroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MU-JHU CARE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MU-JHU CARE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primarily objective of this study is to assess the effect of switching from Tenofovir
      Disoproxil Fumurate (TDF) to TAF based ART on bone mass and turnover among women on DMPA for
      contraception. HIV virologically suppressed women on DMPA will be switched from their TDF
      based regimen to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy速) in
      a randomized fashion. HIV infected women on TDF and non-hormonal contraception will be
      switched to Biktarvy速).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">June 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in bone mineral density</measure>
    <time_frame>2 years</time_frame>
    <description>We will assess percent change in BMD among DMPA users who switch to B/F/TAF compared to DMPA users remaining on TDF based ART</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in trabeculae bone score (TBS)</measure>
    <time_frame>2 years</time_frame>
    <description>We will assess percent change in TBS among DMPA users who switch to B/F/TAF compared to DMPA users remaining on TDF based ART</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in bone biomarkers</measure>
    <time_frame>2 years</time_frame>
    <description>We will compare changes in bone turnover markers (CTX and P1NP) in B/F/TAF switchers with and without DMPA use</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Bone Loss</condition>
  <arm_group>
    <arm_group_label>DMPA+ and TDF+</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIV-infected women on DMPA, and TDF containing ART.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMPA+ and B/F/TAF+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected women on DMPA, and B/F/TAF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DMPA- and B/F/TAF+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected women on non hormonal contraception, and B/F/TAF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy速).</description>
    <arm_group_label>DMPA+ and B/F/TAF+</arm_group_label>
    <arm_group_label>DMPA- and B/F/TAF+</arm_group_label>
    <other_name>Biktarvy速)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF/3TC/EFV or DTG or NVP</intervention_name>
    <description>A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.</description>
    <arm_group_label>DMPA+ and TDF+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DMPA</intervention_name>
    <description>Two thirds of the women will be on DMPA for contraception.</description>
    <arm_group_label>DMPA+ and B/F/TAF+</arm_group_label>
    <arm_group_label>DMPA+ and TDF+</arm_group_label>
    <other_name>Depo-provera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20 through 40 years (inclusive) at screening, verified per site SOPs

          -  Able and willing to provide written informed consent to be screened for and to take
             part in the study.

          -  Able and willing to provide adequate locator information, as defined in site SOPs

          -  Previously participated in the BONE: CARE study

          -  Per participant report, plans to stay in the study catchment area in the next 24
             months

          -  Per participant report, willing to continue using similar contraceptive method as in
             the BONE: CARE study.

        Exclusion Criteria:

          -  Currently pregnant/ breastfeeding or was pregnant/ breastfeeding in the last 6 months
             prior to screening

          -  Intentions to get pregnant in the next two years

          -  History of active tuberculosis

          -  Pathologic bone fracture not related to trauma (ever)

          -  Has pre-existing condition known to affect bone metabolism (e.g. thyrotoxicosis,
             tuberculosis, diabetes mellitus, liver or renal disease)

          -  Is taking the following medications known to interfere with bone metabolism (steroids,
             anti-convulsants, bisphosphonates, cancer drugs, etc.).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>20 - 40 year old HIV-infected non pregnant women</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavia Kiweewa Matovu, MBChB, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>MU-JHU CARE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judith Mbanza, MA</last_name>
    <phone>+256414541044</phone>
    <email>jmbanza@mujhu.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Nolan, M.B.B.S, MPH</last_name>
    <phone>+256414541044</phone>
    <email>mnolan@mujhu.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MU-JHU Care Limited</name>
      <address>
        <city>Kampala</city>
        <zip>+256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Kiweewa Matovu, MBChB, MSc</last_name>
      <phone>+256414541044</phone>
      <email>fmatovu@mujhu.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

